Novo Nordisk | NVO - Assets


Novo Nordisk reported DKK76.18B in Assets for its fiscal quarter ending in June of 2025.





Assets Change Date
ANI Pharmaceuticals USD 1.42B 18.41M Mar/2026
Aurora Cannabis CAD 601.09M 174.2M Mar/2026
Bausch Health Companies USD 24.5B 1.87B Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Canopy Growth CAD 1.12B 12.54M Mar/2026
Corcept Therapeutics USD 814.88M 21.77M Mar/2026
Drreddys Laboratories INR 579.35B 573.08B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Novartis USD 118.53B 7.58B Mar/2026
Novo Nordisk DKK 559.22B 16.32B Mar/2026
Novo Nordisk DKK 76.18B 412.98B Jun/2025
Pacira USD 1.21B 56.38M Mar/2026
Perrigo USD 7.98B 551.9M Mar/2026
Phibro Animal Health USD 1.45B 39.56M Mar/2026
Prestige Brands USD 3.49B 430K Mar/2026
Sanofi EUR 128.02B 1.22B Mar/2026
Supernus Pharmaceuticals USD 1.5B 48.08M Mar/2026
Zoetis USD 15.15B 313M Mar/2026